HIV Medicine · 2019 · 10 citations · 78 references
PharmacyHealth SciencesInfectious DiseasesGood Clinical PracticeHiv ControlMedical MicrobiologyAntifungal StewardshipAntiretroviral TherapyGuideline DevelopmentGuideline ImplementationOpportunistic Infection ManagementOpportunistic Infection PreventionAppropriate Empiric TherapyCandida Infection ManagementGuideline Development For ProphylaxisGuideline MethodologyHiv-associated Opportunistic InfectionsHiv-associated Oral CandidiasisInvasive Candidiasis TreatmentOpportunistic Infection Prophylaxis
Full details of the guideline development process, including conflict of interest policy, are outlined in the BHIVA guideline development manual which was last updated in 2014 (see https://www.bhiva.org/file/jgCacHqmuxZFL/GuidelineDevelopmentManual.pdf). The scope, purpose and guideline topics were agreed by the writing group. Questions concerning each guideline topic were drafted and a systematic literature review undertaken by an independent information scientist (Jacoby Patterson). The search questions (the populations, interventions, comparators and outcomes [PICOs]), are outlined in Appendix 1, and the search strategy in Appendix 2. Details of the methodology can be found on the BHIVA website (https://www.bhiva.org/file/5d514ec9b503d/OI-guidelines-methods-general.pdf). For the current guidelines, PubMed, Medline, Embase and the Cochrane Library were searched for English language publications between January 2010 and March 2018, the period since the last candidiasis guidelines published by BHIVA. Searches were conducted using the following terms: HIV or AIDS and candidosis, candidiasis, Candida spp., Candida albicans, non-albicans Candida, oropharyngeal candidiasis, candida (o)esophagitis, vulvo(-)vaginal candidiasis or mucosal candidiasis. Abstracts from selected conferences (BHIVA, Conference on Retroviruses and Opportunistic Infections, Interscience Conference on Antimicrobial Agents and Chemotherapy and Infectious Diseases Society of America) were also searched for the same period. Articles already cited in the 2011 BHIVA/British Infection Association (BIA) guidelines for the treatment of opportunistic infection in HIV-seropositive individuals were also considered for the current guidelines. Definitions used are summarised in Appendix 3. Appendix 4 outlines the literature selection process. In total, 1133 abstracts were initially screened by the information scientist and 355 identified on the basis of clinical relevance, match to the PICO questions and level of detail. Exclusion factors were non-human studies, case reports and insufficient detail to allow thorough assessment. The 355 identified abstracts were assigned to PICO questions and subsequently reviewed by at least three members of the writing group. Each PICO question was initially reviewed by one member of the writing team, with expertise in the field, who reviewed the papers for relevance, prioritising meta-analyses and randomised control trials where available. They provided an initial summary, compiling evidence and combining this with evidence collected in the last guideline. The individual summaries were then formatted into an initial draft guideline and all authors then reviewed the recommendations against the evidence and also had the opportunity to review the data and add additional evidence having reviewed the assembled abstracts. For each topic and healthcare question, summated evidence was then evaluated by all writing group members. Using the modified Grading of Recommendations Assessment, Development and Evaluation (GRADE) system (see BHIVA website: https://www.bhiva.org/BHIVA-guideline-development), writing group members were responsible for assessing and grading the quality of evidence for predefined outcomes across studies and developing and grading the strength of recommendations. All writing group members received training in the use of the modified GRADE criteria. Before final approval by the writing group, the guidelines were published online for public consultation and external peer reviews were commissioned. As part of this process, input was sought from BIA and from patient groups. The writing group responded to all points raised in the consultation and review. [Correction added on 14 October 2020, after first online publication: On page 4, the words ‘the partner organisation’ were removed from the last paragraph.] Candida spp. are common commensals in the general population and may be cultured from the oral cavity, gastrointestinal tract and genital tract of up to 75% of individuals 1. Surveillance studies have consistently identified higher rates of mucosal carriage of Candida in men and women with HIV 2, 3, with mucosal candidiasis representing the primary pathological manifestation. Oropharyngeal candidiasis is the commonest opportunistic infection to affect individuals with HIV and occurred in 80–90% of patients in the era prior to combination antiretroviral therapy (cART) 4, 5. In recent cohort reviews, the relative frequency of oropharyngeal candidiasis has remained high compared to other opportunistic infections despite reduction in the overall prevalence in association with cART 6, 7. According to NA-ACCORD cohort data from North America, oesophageal candidiasis was the leading opportunistic infection by 2010 with an incidence of 0.34 (0.29–0.38) events per 100 person-years in 2008–2010 7. In studies conducted from the era prior to cART to the current era, oesophageal candidiasis has been reported as the AIDS-defining indicator illness in 11–51% of cases 5, 8-11. The most recent of these studies, which examined late presenters with HIV, defined as those with CD4 counts <350 cells/mm3 or with an AIDS-defining illness, reported the highest contribution of oesophageal candidiasis 11. Although vaginal colonisation by Candida occurs more frequently in women living with HIV, vulvovaginitis occurs sporadically, and is similar in nature to that observed in immunocompetent people 5. Some studies have shown an increase in vulvovaginal candidiasis with HIV, but severity or recurrence is not increased and, unlike oropharyngeal candidiasis, there is no relationship with CD4 T cell count 12, 13. Therefore, the impact of HIV appears to be less for vulvovaginal than for oropharyngeal candidiasis. Invasive candidiasis (candidaemia) represents a growing nosocomial threat attributable to individual host factors (e.g. immunosuppression) and healthcare-related risk factors. People living with HIV are increasingly at risk in the context of undergoing intensive treatments for emerging comorbidities that expose them to HIV-independent candidaemia risk factors (e.g. central venous catheter placement or intensive care admission). Studies have not demonstrated good evidence of a further increased risk in people living with HIV in the presence of these HIV-independent risk factors, and management is recommended as for HIV-seronegative individuals 5, 14-17. Several reviews and guidelines cover management of this condition 14, 16, 17. Candida albicans remains the leading cause of Candida infections globally but the distribution of non-albicans Candida spp. shows geographical variation 18. Non-albicans Candida spp. occur particularly in association with previous azole therapy and advanced immunosuppression 5. HIV-specific data for oropharyngeal or vulvovaginal infections reflect the trends in international surveillance data; C. albicans remains most prevalent. The rates of non-albicans Candida spp. continue to rise to approximately 30% in many cohorts, influenced by geographical location and resource setting 3, 19-21. Recent US data suggest that C. albicans is responsible for 62–68% of oropharyngeal Candida spp. infections and 73% of vulvovaginal Candida spp. infections 2, 22. C. glabrata (17–21% of cases) and C. dublinensis (6–12%) are leading causes of non-albicans Candida infections in US and South African populations 22-24. Antifungal azole resistance may be an intrinsic feature, as observed for fluconazole in C. krusei, or may be the result of evolution during recurrent drug exposure, as for fluconazole in C. albicans or C. dublinensis 5, 16. For some species such as C. glabrata, azole resistance may be induced by drug exposure but background resistance to fluconazole is also prevalent. Therefore, detection of C. glabrata should prompt treatment with an alternative agent unless fluconazole susceptibility is microbiologically demonstrated 16. The increased prevalence of innately fluconazole-resistant Candida spp. and Candida spp. with reduced-susceptibility to echinocandins and many other antifungals highlights the need for accurate speciation and susceptibility testing 25-28. C. auris, an inherently multidrug-resistant new Candida spp., has recently emerged as a cause of candidaemia; it is an infection control challenge, particularly in intensive care units and after surgery, but has not yet been linked with particular problems in HIV 29. The immunological response against Candida spp. at the gastrointestinal mucosa or on skin surfaces is highly dependent on T helper (Th)17 T cells 30. This T cell subset is disproportionately depleted during the early stages of HIV-associated T cell decline and this disrupts host surveillance, favouring pathogenicity 31, 32. This in part reflects the fact that the Candida-specific Th17 T cells are highly permissive to HIV infection 31. Vulvovaginal candidiasis may be less influenced by Th17 T cell function and more influenced by dysbiosis and alterations in the vaginal pH. The oral microbiome also shows reduced diversity and increased Candida spp. colonisation in association with HIV-related immunosuppression, but these changes are at least partially reversible with cART 19, 33, 34. Individuals receiving cART who have oesophageal candidiasis show evidence of impaired T cell responses to C. albicans even after 2 years of therapy. Thus, increased susceptibility due to impaired immunity may remain despite cART 35. Clinical risk factors for oropharyngeal candidiasis other than immunosuppression in people living with HIV include injection drug misuse and tuberculosis. Other more general predisposing factors, not specifically related to HIV, include the presence of multispecies biofilms due to poor oral hygiene, dental caries, diabetes mellitus, use of inhaled/topical or systemic corticosteroids and poorly controlled gastro-oesophageal reflux disease (GORD), since Candida spp. thrive in an acidic environment. However, Candida spp. have also been found in the presence of proton pump inhibitors in some studies suggesting there may be an optimal pH level to inhibit growth 21, 23, 36. Oropharyngeal candidiasis is associated with worsening immunodeficiency 37 and in the absence of cART predicts the development of AIDS at a median of 25 months 38. The most familiar clinical appearance of oropharyngeal candidiasis is of easily removable, curd-like white plaques, underneath which lies raw or bleeding mucosa (so-called ‘pseudomembranous’ candidiasis). Other oral presentations include: an erythematous form, with patchy reddening of the mucosa and depapillation of the dorsal surface of the tongue 39; hyperplastic candidiasis, with white plaques that cannot be scraped away; and angular cheilitis with painful of the The are and the may be with the clinical appearance of oral candidiasis. Vulvovaginal candidiasis in women living with HIV with similar to that in women HIV with and curd-like 5, 14, are and to to clinical associated with to Candida spp. on should the of an alternative the patient with oesophageal candidiasis of such as increased and of are also use of cART and the decline in opportunistic the for gastrointestinal in people living with HIV is not due to candidiasis and can also is a risk for oesophageal candidiasis since Candida spp. thrive in acidic and can more easily In a people living with HIV who to gastrointestinal reported higher for a of gastrointestinal but were of oesophageal candidiasis and were in fact more of in people living with not to treatment of oesophageal candidiasis or associated with should also the of oesophageal Although oesophageal is not an people living with HIV who with and in particular those with or factors associated with oesophageal in people living with HIV, such as use and should have to oesophageal candidiasis oropharyngeal evidence of plaques is and occurs in a of cases in most studies Therefore, where a patient of in the absence of oropharyngeal candidiasis, other such as and be However, one recent conducted in the cART era, demonstrated that of patients with oesophageal candidiasis had no of oropharyngeal Candida, were and had CD4 T cell counts This that some of the clinical associated with oesophageal candidiasis in the era use of cART may be in an era of antiretroviral therapy and of immunosuppression Oropharyngeal and oesophageal candidiasis are clinical and has not been due to the of in the absence of clinical Recent studies even in the era of antiretroviral can oropharyngeal candidiasis with and which the of detection This that this is for mucosal infections by Candida spp. is that and in of risk resistance in Candida should be for individuals with and of infection despite therapy or who recurrent This to the of an infection in the context of response despite the of alternative or additional oropharyngeal candidiasis occurs in the context of to or the presence of risk factors and has a primary for the selection of non-albicans Candida and of fluconazole-resistant species due to exposure The of should be to the Candida spp. to selection of therapy and to a for susceptibility C. is fluconazole and may be to and other C. glabrata fluconazole is more but C. glabrata infection following exposure with many fluconazole are for for (see In a of an from a oral such as the or mucosa or a vaginal the vaginal with use of and should be examined by for the presence of cells and In cases of recurrent or poor or should also be for vaginal is also an with high rates in studies of individuals In patients to oral or vaginal the of species to initial therapy In cases the absence of or to to initial therapy may suggest This should prompt to other such as However, these should be examined by with and also for Candida spp. may be cultured on are frequently on and should for such as are most used for speciation but may have against some non-albicans may be more and increasingly are used as is by and the presence of Candida in In all cases with disease and for with or recurrent infection the Candida should be and used to the of candidiasis, such as have no for mucosal disease oesophageal candidiasis can be other opportunistic infections or oesophageal are to be less by should be used in cases with of oesophageal candidiasis which to to initial cases oropharyngeal candidiasis, or cases where an alternative oesophageal condition is such as oesophageal in cases with where may have been the initial should such as white or can be for as outlined of therapy is to risk factors to recurrence and this should be with therapy. oral and of oral biofilms is a of the management of oral infection as biofilms are inherently to therapy The of an updated Cochrane systematic review in 2010 the that fluconazole therapy is consistently associated with rates of compared to therapy for the treatment of oropharyngeal candidiasis is the most selected systemic azole against oropharyngeal candidiasis and should be for 100 can be used for in first with the higher or more for disease with a or cases of after previous fluconazole In the and should fluconazole resistance fluconazole therapy. therapy may be used in oropharyngeal candidiasis. is associated with of from the a higher and reduced Therefore, this as an alternative to fluconazole in cases a of recurrence and there may be to an alternative to such as in the setting of fluconazole or C. treatment is as of for where include or oral than and all for recent randomised clinical demonstrated that a the was to However, there is a of data on or the on with such as and should be used with are considered to Clinical response rates a of in these studies with therapy from and, where have been to rates with However, as the have been associated with rates of and rates In to or systemic emerging evidence the of in oropharyngeal candidiasis the need for good and the use of This is for who are at particular risk of fluconazole resistance due to which can resistance development treatment should be to cases with clinical with associated risk factors. or therapy remain the for initial therapy. Other should be used after consultation with an disease or clinical and in As with oropharyngeal candidiasis, should on risk factors in to therapy for candidiasis. fluconazole and have demonstrated in the treatment of oesophageal candidiasis, with fluconazole response rates of approximately in the era prior to for remains the with of used for disease Although has been used as an and fluconazole remains the is used it should be as the of is less than that of the oral and is more dependent on to which is associated with advanced HIV the of the and drug oral has than the but shows in as is also by and is reduced in to fluconazole Therefore, even with oral is in patients with CD4 T cell counts and those systemic and treatment with fluconazole is the in most pump inhibitors for oesophageal also inhibit the of fluconazole in cell and these during treatment of the stages of oesophageal or oropharyngeal should be considered a period is not an treatment such as therapy or use of an (e.g. may be an is and should not be with such as is in the and is the azole of in patients treatment with such is to use as the least azole in patients with treatment with an can also be considered (see In in patients who cannot an oral fluconazole is an this with an infection In cases where the patient has not a response and where are alternative should be considered than of therapy. there is clinical or of oropharyngeal candidiasis, poor to with poor drug for oral therapy or poor of oral therapy may be The should be used in consultation with an disease or other infection are for disease or including to or to oral therapy. and have Although there may be some of oral of or the contribution of this is in oropharyngeal or oesophageal candidiasis. drug is to for of and of but not allow for that the oral may have and in the therapy of oropharyngeal candidiasis is The of should not be used as outlined and have increased in with fluconazole which also use and for the HIV website or similar oral has demonstrated against oropharyngeal candidiasis is for a of cases due to and in with fluconazole is for use fluconazole resistance is demonstrated but the is to there is disease in the absence of fluconazole resistance (e.g. drug a of an oral as in a patient with or in cases where there is to Clinical response rates for disease with oral were than in the era oral is an alternative and has been associated with responses in with fluconazole The of therapy can be to in All azole other than fluconazole or of function initially in the first and then or 14 of in patients receiving not this therapy should be in patients with drug is using or as outlined patients may be to therapy and oral fluconazole or of response to oral fluconazole or other of poor to or poor of In these cases can include fluconazole or the outlined for oesophageal candidiasis. are a of that can be considered for the treatment of oesophageal disease As is the case for oropharyngeal candidiasis, should an alternative and should to early not already to fluconazole should be used with the input of an infection to for oesophageal candidiasis include the and of and drug to and to for systemic used for oesophageal candidiasis the of drug for the agent is As outlined there are many between these and antiretroviral or other to people living with The for these and other should be prior to has demonstrated against candidiasis, including candidiasis to recently in of by or by have been shown to be to fluconazole 100 with in patients with oesophageal candidiasis In with and has it is a and a may increase the exposure of that are particularly those with a which may of or other with a may also be than some of these other and is not to cause the or associated with is also against and was found in a randomised controlled to be as but more than fluconazole it should be for cases where or are not However, the of such as and and the associated with the for as compared to in drug and the for drug these should be used in with In other such as azole resistance or or to an oral or an it may be to an In these to susceptibility may include the and (see for or with these should be for oesophageal candidiasis with the used as first and for response or have all demonstrated in randomised clinical trials in oesophageal candidiasis, and the need to the use of and use should be for include cases where fluconazole therapy is or not oral therapy cannot be or where infection is due to with reduced susceptibility to quality of In clinical trials of oesophageal candidiasis, was as but less than and was against fluconazole-resistant and have shown defined as response with or in clinical to fluconazole in the treatment of oesophageal candidiasis has in a to that of demonstrated a and was associated a higher of these is by the of fluconazole used in the studies For oropharyngeal candidiasis a initially the use of by an alternative azole or an there are no azole For oesophageal candidiasis the or by an Vulvovaginal candidiasis is as or Vulvovaginal candidiasis is in the same in people living with HIV as it is in the azole therapy has been shown to be to oral therapy in a systematic review of vulvovaginal candidiasis The agent is therapy can be as a of fluconazole and is in some guidelines (e.g. the Association for and HIV with therapy as an For disease with or the oral can be after For recurrent disease the oral fluconazole can be for three and then for Vulvovaginal candidiasis due to non-albicans Candida spp. with reduced fluconazole susceptibility (e.g. C. may be with 100 units but may be for 14 to therapy for non-albicans Candida are vaginal with for 14 or in data from HIV-seronegative individuals and quality of information is in the guidelines for vulvovaginal candidiasis are no clinical data to the treatment of candidiasis in individuals living with In candidiasis should be with systemic therapy as in other patient quality of guidelines (e.g. from the Society of Clinical and Infectious Diseases and from the Infectious Society of America) have of care for candidiasis in this setting and should be to treatment which is influenced by patient factors and of infection 14, are also no data on the treatment of C. in people living with HIV and C. infections should also be in with emerging for is not and is associated with the of As with other opportunistic cART of oropharyngeal or oesophageal candidiasis. Thus, the most strategy for patients with candidiasis is to cART 6, 7. should be considered with to antiretroviral and (see review and of the impact of cART on opportunistic infections in and that cART the incidence of mucosal candidiasis with oral candidiasis one of the opportunistic infections with the impact in a setting the risk of oesophageal candidiasis that cART is associated with a reduced of oesophageal candidiasis are reports of candidiasis associated with including a case of Candida leading to the decline in candidiasis and with there remains a level in people living with HIV that in HIV-seronegative individuals 11. of azole antifungals between of recurrent oropharyngeal candidiasis is not as this may be associated with of candidiasis quality of In the era, candidiasis was increasingly common in patients who had received with azole antifungals and was due to infection with species other than C. albicans such as C. and C. glabrata, or of C. albicans However, fluconazole treatment not to a increase in oropharyngeal or oesophageal candidiasis in an this to treatment in people living with HIV with to cART The of azole therapy to including candidiasis, during treatment of is in the BHIVA guidelines living with an individual with a for HIV Oropharyngeal clinical appearance of candidiasis in the or with or plaques, of or or at the of the in the presence or absence of such as and testing has been it should Candida spp. or in absence to an alternative or in the presence or with of oropharyngeal candidiasis with or testing has been it should Candida spp. or in absence to an alternative Vulvovaginal a clinical of or curd-like from the with or associated such as and external in association with of on or Invasive of Candida spp. by from a such as the an to development of a clinical associated with disease The writing group for and HIV at for a for independent literature and for The writing group also the HIV who to the consultation and the for
78
Chronic Mucocutaneous Candidiasis in Humans with Inborn Errors of Interleukin-17 Immunity
Anne Puel, Sophie Cypowyj, Jacinta Bustamante et al. · Science · 2011 · 1K citations
Barbara D. Alexander, Melissa D. Johnson, Christopher D. Pfeiffer et al. · Clinical Infectious Diseases · 2013 · 776 citations · Full text